| Avastin (bevacizumab) / Roche |
EAGLE, NCT05491811: Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation |
|
|
| Recruiting | 2 | 58 | RoW | Ensartinib, Bevacizumab, MIL60 | Sun Yat-sen University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shenyang Chest Hospital, Hebei Medical University Fourth Hospital, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Guangzhou Institute of Respiratory Disease, Central People's Hospital of Zhanjiang, Guangdong Provincial Agricultural Reclamation Central Hospital, Wuhan Union Hospital, China, West China Hospital, The First Affiliated Hospital with Nanjing Medical University, Yuebei People's Hospital, Yunnan Cancer Hospital | Non-Small Cell Lung Cancer | 06/24 | 12/26 | | |
NCT05616390: Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Sintilimab, IBI308, Bevacizumab, Liver Protective Support Therapy | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma | 11/23 | 11/25 | | |
NCT06138769: Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 50 | RoW | Lenvatinib | Asan Medical Center, Eisai Inc., Chonnam National University Hospital, Seoul National University, Gangneung Asan Hospital, Ulsan University Hospital, Chosun University Hospital, Dong-A University Hospital, Bundang CHA Hospital, Seoul National University Bundang Hospital, Yonsei University, Hanyang University Seoul Hospital, Chungnam National University Hospital, Saint Vincent's Hospital, Korea, Gyeongsang National University Hospital, Ewha Womans University, Chungbuk National University Hospital, Severance Hospital, Gachon University Gil Medical Center, The Catholic University of Korea, Bucheon St. Mary's Hospital | Hepatocellular Carcinoma | 11/26 | 11/27 | | |
BRAND, NCT06141265: Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab |
|
|
| Recruiting | 2 | 116 | RoW | Niraparib | Peking University Cancer Hospital & Institute | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | 09/26 | 09/27 | | |
| Active, not recruiting | 2 | 139 | RoW | A1: Pyrotinib with nab-paclitaxel, SHR1258, A2: nab-paclitaxel, B1: everolimus with nab-paclitaxel, B2: nab-paclitaxel, C1: PD-1 with nab-paclitaxel and famitinib, Camrelizumab, SHR1210, C2: nab-paclitaxel, D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine, Bevacizumab (BP102), D2: nab-paclitaxel, with maintenance of capecitabine, E1: everolimus with nab-paclitaxel, E2: nab-paclitaxel | Fudan University | TNBC - Triple-Negative Breast Cancer | 05/23 | 12/24 | | |
ProtonAB, NCT06133062: Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 45 | RoW | Atezolizumab, Bevacizumab, Proton radiotherapy | Chang Gung Memorial Hospital | Hepatocellular Carcinoma Non-resectable | 09/28 | 09/30 | | |
NCT05266846: Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK |
|
|
| Recruiting | 2 | 78 | RoW | Pembrolizumab injection, pemetrexed, Bevacizumab, CISPLATIN | Hunan Province Tumor Hospital | ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy | 11/26 | 02/27 | | |
NCT06152822: Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases |
|
|
| Recruiting | 2 | 30 | RoW | pyrotinib+capecitabine+bevacizumab | Tongji Hospital | Breast Cancer With Brain Metastases | 11/24 | 11/25 | | |
NCT01950390: Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery |
|
|
| Active, not recruiting | 2 | 169 | US | Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy | National Cancer Institute (NCI) | Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma | 10/21 | 01/25 | | |
CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels |
|
|
| Active, not recruiting | 2 | 177 | Europe | FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 12/24 | 12/25 | | |
NCT04051606: Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma |
|
|
| Active, not recruiting | 2 | 14 | US | Regorafenib | Case Comprehensive Cancer Center | Recurrent Glioblastoma | 10/24 | 10/24 | | |
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor |
|
|
| Active, not recruiting | 2 | 80 | US | Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab | SCRI Development Innovations, LLC, Genentech, Inc. | Non-Small Cell Lung Cancer, Solid Tumor | 07/24 | 07/24 | | |
NCT04974944: First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer |
|
|
| Recruiting | 2 | 172 | RoW | Camrelizumab, SHR1210, Apatinib, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab | Sun Yat-sen University | Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer | 12/23 | 12/24 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
| Recruiting | 2 | 45 | RoW | Aatezolizumab plus Bevacizumab, Ticentriq plus Avastin | Tae Won Kim | Hepatocellular Carcinoma | 12/23 | 12/25 | | |
| Recruiting | 2 | 42 | RoW | Multifocal Stereotactic Radiotherapy, Atezolizumab Injection [Tecentriq], Bevacizumab | Fudan University, Roche Pharma AG | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
NCT05394233: Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC |
|
|
| Not yet recruiting | 2 | 20 | RoW | Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed | Sichuan Cancer Hospital and Research Institute | Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation | 12/23 | 06/24 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT05797883: FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOX/FOLFIRI | China Medical University, China | Unresectable or Metastatic Colorectal Cancer | 12/23 | 12/24 | | |
NCT05754736: Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations. |
|
|
| Recruiting | 2 | 50 | RoW | Ametinib combined with bevacizumab, Third-generation TKI combined with antivascular targeting drug | The Second Affiliated Hospital of Shandong First Medical University | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT05785325: RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | RC48-ADC plus Bevacizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer | 12/23 | 12/24 | | |
NCT06433869: The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites |
|
|
| Recruiting | 2 | 60 | RoW | serplulimab, PD-1 inhibitor, Bevacizumab, rmhTNF-NC, recombinant human tumor necrosis factor | Sun Yat-sen University | Malignant Ascites | 12/26 | 12/26 | | |
| Recruiting | 2 | 214 | Europe | Regorafenib, panitumumab, Panitumumab, regorafenib | Gruppo Oncologico del Nord-Ovest, Bayer, Amgen | Colorectal Cancer | 12/24 | 06/25 | | |
NRG-GY023, NCT04739800: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents |
|
|
| Active, not recruiting | 2 | 120 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral) | National Cancer Institute (NCI), NRG Oncology | Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma | 01/23 | 01/25 | | |
NCT04135690: HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial |
|
|
| Recruiting | 2 | 60 | RoW | Hepatic arterial infusion chemotherapy, Toripalimab, Sorafenib, systemic treatment | Sun Yat-sen University | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
FOBECAMS, NCT06176885: Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Camrelizumab | yue junhan | Colorectal Cancer | 12/25 | 12/26 | | |
NCT06182800: Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy |
|
|
| Not yet recruiting | 2 | 35 | NA | Adebrelimab Combined with Bevacizumab and Docetaxel | The First Affiliated Hospital of Xinxiang Medical College | Non-small Cell Lung Cancer | 06/25 | 12/25 | | |
| Active, not recruiting | 2 | 95 | Europe, RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin, Carboplatin, Paclitaxel, Pemetrexed, Alimta | ETOP IBCSG Partners Foundation, Roche Pharma AG | EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC | 12/24 | 12/24 | | |
ChiCTR2000035881: Efficacy and safety of hypofractionated re-radiation therapy plus bevacizumab versus bevacizumab alone in the treatment of recurrent glioblastoma: a prospective, single-center, phase II, parallel, randomized, controlled trial |
|
|
| Not yet recruiting | 2 | 129 | | HFRT: 40Gy/15Fx/3weeks ;bevacizumab ;bevacizumab | Fudan University Huashan Hospital; Fudan University Huashan Hospital, Investigator-initiated clinical studies that are self-funded or supported by related funding projects | Recurrent glioblastoma | | | | |
NCT03937830: Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma |
|
|
| Recruiting | 2 | 72 | US | durvalumab, Doxorubicin-Eluting Beads, TACE, bevacizumab, Tremelimumab | National Cancer Institute (NCI) | Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 12/25 | 12/25 | | |
NCT04832776: FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases |
|
|
| Recruiting | 2 | 160 | RoW | Cetuximab, Bevacizumab, FOLFOXIRI | Fudan University | Liver Metastasis Colon Cancer | 12/23 | 12/25 | | |
NCT04952571: Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM) |
|
|
| Suspended | 2 | 94 | RoW | Camrelizumab and Bevacizumab | Beijing Sanbo Brain Hospital | Recurrent Glioblastoma | 12/23 | 12/24 | | |
ChiCTR2100047016: Pamiparib in combination with bevacizumab in patients with recurrent or metastatic ovarian cancer who had previously received PARPi |
|
|
| Recruiting | 2 | 29 | | pamiparib 60 mg BID plus bevacizumab 7.5 mg/kg Q3W | Hunan Provincial Tumor Hospital; Hunan Provincial Tumor Hospital, self-funded | ovarian cancer | | | | |
ChiCTR2100053431: Raltitrexed + Oxaliplatin (SALOX) plus Bevacizumab as the First Line Treatment in Patients with Advanced Colorectal Cancer: An Open-Label, Multicenter, Prospective Study |
|
|
| Recruiting | 2 | 90 | | Raltitrexed 3 mg/m^2 + Oxaliplatin 130 mg/m^2 + Bevacizumab 7.5 mg/kg | Medical Oncology Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Self-funded | Colorectal cancer | | | | |
ChiCTR2200055496: A single-center, phase II, exploratory clinical study on the efficacy and safety of bevacizumab injection combined with systemic chemotherapy in the treatment of malignant mesothelioma thoracic and ascites |
|
|
| Recruiting | 2 | 30 | | Bevacizumab combined with systemic chemotherapy | Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital, None | Malignant pleural and peritoneal mesothelioma | | | | |
NCT05400902: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 17 | RoW | HAIC Combined with Tislelizumab and Apatinib | Binkui Li | Intrahepatic Cholangiocarcinoma | 12/23 | 12/23 | | |
LUN 17-139, NCT03786692: Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC |
|
|
| Recruiting | 2 | 117 | US | Arm A, Arm B | Fox Chase Cancer Center, National Comprehensive Cancer Network | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | 01/25 | 01/27 | | |
NCT04683965: Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 27 | RoW | Pemetrexed, TAS-102, LONSURF, Bevacizumab, Avastin | The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Colorectal Neoplasms | 01/24 | 05/24 | | |
LIVERPEARL, NCT04595266: Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease |
|
|
| Recruiting | 2 | 48 | Europe | FOLFOX regimen, Leucovorin/Fluorouracil/Oxaliplatin, Anti-EGFR or Bevacizumab, monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut), LIVERPEARLS-Irinotecan, Chemoembolization of Irinotecan in hydrogel microspheres | Grupo Espanol Multidisciplinario del Cancer Digestivo | Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer | 01/24 | 01/25 | | |
| Recruiting | 2 | 390 | Europe, Japan | Chemotherapy, Bevacizumab-Awwb, Niraparib | ARCAGY/ GINECO GROUP | Ovarian Cancer | 02/27 | 02/30 | | |
STRATUM, NCT05377034: Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients |
|
|
| Recruiting | 2 | 176 | RoW | SIRT-Y90 with Atezolizumab + Bevacizumab, SIRT-Y90 with Placebo (IV) | National Cancer Centre, Singapore, Hoffmann-La Roche, Sirtex Medical, Singapore Clinical Research Institute | Locally Advanced Hepatocellular Carcinoma | 04/25 | 10/26 | | |
NCT05760599: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T |
|
|
| Recruiting | 2 | 30 | RoW | Candonilimab, Bevacizumab | Shi Ming | Hepatocellular Carcinoma | 01/24 | 07/24 | | |
NCT06184698: Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | NA | liposomal irinotecan, nal-IRI, 5-FU, Fluorouracil, LV, Calcium folinate, Bevacizumab, Avastin | Hebei Medical University Fourth Hospital | Colorectal Cancer | 12/24 | 12/25 | | |
NCT06218810: Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 53 | RoW | Cadonilimab + bevacizumab + FOLFOX | Fudan University | Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab | 12/25 | 12/26 | | |
NCT06360042: Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC |
|
|
| Recruiting | 2 | 111 | RoW | Adebrelimab plus Apatinib, Adebrelimab plus Bevacizumab, Camrelizumab plus Apatinib | Peking University Cancer Hospital & Institute | Unresectable Hepatocellular Carcinoma | 03/27 | 03/28 | | |
NCT05192798: Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC |
|
|
| Recruiting | 2 | 128 | RoW | Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab | First Affiliated Hospital Bengbu Medical College | Triple-negative Breast Cancer | 01/25 | 06/25 | | |
| Active, not recruiting | 2 | 41 | Europe | Atezolizumab-Bevacizumab, Tecentriq-Avastin | Fundación GECP | Non Small Cell Lung Cancer | 11/24 | 01/25 | | |
|
NCT01217931: Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial |
|
|
| Active, not recruiting | 2 | 180 | US | Pazopanib, GW786034, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Everolimus, Afinitor, RAD001 | M.D. Anderson Cancer Center, Novartis | Kidney Cancer | 01/25 | 01/25 | | |
NCT05199285: A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab |
|
|
| Recruiting | 2 | 40 | US | Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo | Academic and Community Cancer Research United, National Cancer Institute (NCI) | BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma | 01/24 | 01/27 | | |
NCT02884648: Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery |
|
|
| Recruiting | 2 | 35 | US | Bevacizumab, Avastin, Anti-VEGF Monoclonal Antibody, rhyMab-VEGF | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 02/25 | 02/25 | | |
GASTO-1086, NCT05468242: Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy |
|
|
| Recruiting | 2 | 116 | RoW | Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy, Tislelizumab | Sun Yat-sen University | Stage III Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
NCT05267366: Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC |
|
|
| Recruiting | 2 | 117 | RoW | PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed | Qingdao Central Hospital | PFS, OS | 02/24 | 07/24 | | |
| Recruiting | 2 | 185 | Europe | Atezolizumab Injection, Bevacizumab, Pertuzumab, Trastuzumab | Gustave Roussy, Cancer Campus, Grand Paris, Hoffmann-La Roche | Breast Cancer | 02/25 | 02/26 | | |
ELEVATE CRC, NCT05330429: Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) |
|
|
| Active, not recruiting | 2 | 135 | Europe, Canada, US, RoW | Magrolimab, GS-4721, Bevacizumab, Irinotecan, CAMPTOSAR®, Fluorouracil, Leucovorin | Gilead Sciences | Metastatic Colorectal Cancer | 03/25 | 11/26 | | |
NCT05665023: Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma |
|
|
| Recruiting | 2 | 37 | RoW | Bevacizumab + modified FOLFIRINOX | Yonsei University | Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 02/24 | 02/25 | | |
NCT06210438: SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases |
|
|
| Not yet recruiting | 2 | 24 | RoW | SHR-A1921 + Bevacizumab | Fudan University | TNBC, Brain Metastasis | 06/25 | 06/26 | | |
STROBE, NCT06377267: Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab ( Trial) |
|
|
| Recruiting | 2 | 100 | Europe | Bevacizumab, Olaparib | Vall d'Hebron Institute of Oncology | Ovarian Cancer | 03/24 | 09/25 | | |
NCT01149850: Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma |
|
|
| Completed | 2 | 50 | US | bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, anti-VEGF rhuMAb, Avastin, recombinant humanized anti-VEGF monoclonal antibody, rhuMAb VEGF, temozolomide, CCRG-81045, M & B 39831, SCH 52365, Temodal, Temodar, TMZ, laboratory biomarker analysis, immunohistochemistry staining method, immunohistochemistry, microarray analysis, gene expression profiling, DNA methylation analysis | Jonsson Comprehensive Cancer Center, Genentech, Inc. | Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma | 12/23 | 12/23 | | |
NCT06293014: TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 224 | RoW | TAS-102+bevacizumab, Trifluridine and Tipiracil Hydrochloride Tablets; bevacizumab, Standard chemotherapy+bevacizumab, Bevacizumab | Henan Cancer Hospital | Colorectal Cancer | 10/25 | 11/26 | | |
| Active, not recruiting | 2 | 30 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin, Cobimetinib, Cotellic | Peter MacCallum Cancer Centre, Australia | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 02/24 | 06/25 | | |
NCT05751343: TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial |
|
|
| Recruiting | 2 | 55 | RoW | TACE-HACI, plus atezolizumab-bevacizumab | Sun Yat-sen University | Hepatocellular Carcinoma | 02/24 | 02/25 | | |
ATHENA, NCT03818061: Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck |
|
|
| Active, not recruiting | 2 | 33 | Europe | Atezolizumab, Tecentriq, Bevacizumab, Avastin | Centre Leon Berard | Head and Neck Neoplasms | 03/24 | 03/24 | | |
NCT04406272: VB-111 in Surgically Accessible Recurrent/Progressive GBM |
|
|
| Active, not recruiting | 2 | 15 | US | VB11, Ofranergene obadenovec, Surgery, Placebo, Bevacizumab, Avastin | Dana-Farber Cancer Institute, Vascular Biogenics Ltd. operating as VBL Therapeutics | Glioblastoma, Recurrent Glioblastoma | 08/24 | 08/24 | | |
NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 134 | US, RoW | SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo | Coherus Biosciences, Inc. | Hepatocellular Carcinoma | 05/25 | 05/26 | | |
ChiCTR2200060643: Efficacy and safety of bevacizumab by hyperthermic intraperitoneal perfusion combined with sindilizumab in the treatment of malignant ascites |
|
|
| Recruiting | 2 | 50 | | bevacizumab by hyperthermic intraperitoneal perfusion combined with sindilizumab | Sichuan University West China Hospital; Sichuan University West China Hospital, self-raised | malignant ascites | | | | |
| Recruiting | 2 | 200 | Europe, US, RoW | DKN-01, LY2812176, FOLFIRI, Bevacizumab, FOLFOX | Leap Therapeutics, Inc. | Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer, Colorectal Cancer Metastatic | 10/25 | 10/25 | | |
|
|
NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer |
|
|
| Recruiting | 2 | 20 | RoW | cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU | Fujian Cancer Hospital | Colorectal Cancer | 03/24 | 03/25 | | |
NCT06282445: Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Adebrelimab, SHR-1316, Oxaliplatin, Capecitabine, Bevacizumab | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Colorectal Cancer Metastatic | 03/25 | 03/26 | | |
NCT06371586: Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC |
|
|
| Recruiting | 2 | 67 | RoW | Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy, PSBP | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Gastric Cancer, Diffuse Type Carcinoma | 03/27 | 03/27 | | |
| Recruiting | 2 | 46 | Europe | 166Holmium TARE, Cetuximab, Panitumumab, 5-Fluorouracil, Bevacizumab, Capecitabine | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer Metastatic | 11/26 | 02/27 | | |
NCT06292689: A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | Cardunolizumab | Zhejiang Cancer Hospital, Akeso, Innovent Biologics, Inc. | Vulvar and Vaginal Cancer | 03/26 | 03/27 | | |
PhotonAB, NCT06339424: Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Atezolizumab, Bevacizumab, Photon radiotherapy | Chang Gung Memorial Hospital | Hepatocellular Carcinoma | 03/29 | 03/31 | | |
NCT05799820: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC |
|
|
| Recruiting | 2 | 60 | RoW | QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine | Qilu Pharmaceutical Co., Ltd. | Colorectal Carcinoma | 03/24 | 09/25 | | |
ChiCTR2100045164: efficacy and safety of Sintilimab plus Bevacizumab for high-risk multiple ground-glass nodules in synchronous stage I non-small cell lung cancer patients: a phase II clinical trial |
|
|
| Not yet recruiting | 2 | 20 | | Sintilimab and Bevacizumab | Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University; Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, self-funded | non-small cell lung cancer | | | | |
| Not yet recruiting | 2 | 32 | NA | FOLFOXIRI and Bevacizumab, 5FU, leucovorin, oxaliplatin, irinotecan and bevacizumab | University of Saskatchewan | Metastatic Colorectal Cancer | 03/26 | 03/26 | | |
ChiCTR2100044245: Sintilimab in combination with bevacizumab as second-line therapy for patients with advanced/recurrent endometrial cancer: a single-arm, open-label exploratory study |
|
|
| Recruiting | 2 | 53 | | Sintilimab+bevacizumab | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Innovent Biologics, Inc | Endometerial cancer | | | | |
NCT05303038: Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy |
|
|
| Recruiting | 2 | 15 | RoW | Cryoablation Combined with Tirelizumab and Bevacizumab | Fudan University | Metastatic Breast Cancer in the Liver | 04/24 | 04/24 | | |
NCT05617430: Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | HAIC, hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W), Sintilimab, IBI308, Bevacizumab Biosimilar IBI305, IBI305 | Wuhan Union Hospital, China | Hepatocellular Carcinoma | 04/24 | 06/24 | | |
NCT06192680: Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 63 | NA | Liposomal irinotecan, nal-IRI, Capecitabine, Xeloda, Bevacizumab, Avastin | Harbin Medical University | Colorectal Cancer | 11/25 | 09/26 | | |
NCT03532295: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas |
|
|
| Active, not recruiting | 2 | 51 | US | Epacadostat, Bevacizumab, Avastin, Radiation therapy, Peripheral blood draw, Retifanlimab, INCMGA00012 | Washington University School of Medicine, Incyte Corporation | Glioma, Glioblastoma | 07/24 | 04/26 | | |
|
NCT04812002: Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy |
|
|
| Recruiting | 2 | 20 | RoW | PD-1 inhibitor， bevacizumab, Camrelizumab for Injection | Women's Hospital School Of Medicine Zhejiang University | Gestational Trophoblastic Neoplasia | 04/24 | 04/26 | | |
NCT06313970: First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients |
|
|
| Not yet recruiting | 2 | 50 | NA | QL1706, Nab-paclitaxel, Gemcitabine, Bevacizumab | Fudan University | Pancreatic Cancer | 04/25 | 04/26 | | |
NCT06364826: Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 60 | NA | Sintilimab, bevacizumab, gemcitabine, IMRT | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 04/26 | 04/26 | | |
ChiCTR2200059119: Prospective, single-arm, single-center phase II clinical study of pamiparib combined with TC regimen and bevacizumab in neoadjuvant therapy for untreated advanced ovarian cancer |
|
|
| Not yet recruiting | 2 | 38 | | Pamipalil + paclitaxel + bevacizumab | Fujian Cancer Hospital; Fujian Cancer Hospital, BeiGene (Beijing) Biotechnology Co., Ltd. | ovarian cancer | | | | |
NCT06160206: Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma |
|
|
| Not yet recruiting | 2 | 134 | US | Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz | Academic and Community Cancer Research United, National Cancer Institute (NCI) | Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma | 11/26 | 11/30 | | |
| Active, not recruiting | 2 | 60 | Europe | Bevacizumab, Tocotrienol | Vejle Hospital | Ovarian Cancer Recurrent | 12/24 | 12/24 | | |
| Recruiting | 2 | 42 | RoW | mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations, mFOLFOX6+Bevacizumab+Sintilimab treatment combinations | Sixth Affiliated Hospital, Sun Yat-sen University | Colorectal Cancer, Immunotherapy | 05/24 | 05/24 | | |
ChiCTR2100047015: Efficacy and safety study for PD-L1 monoclonal antibody with bevacizumab in women with persistent, recurrent, or metastatic cervical cancer |
|
|
| Recruiting | 2 | 40 | | PD-L1 monoclonal antibody + bevacizumab | Peking University Cancer Hospital; Peking University Cancer Hospital, Xisike Clinical Oncology Research Foundation | Cervical Cancer | | | | |
| Recruiting | 2 | 100 | RoW | utidelone, Bevacizumab | Henan Cancer Hospital | Breast Cancer | 05/24 | 05/24 | | |
NCT05640726: The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy |
|
|
| Not yet recruiting | 2 | 30 | NA | PD-1, SCRT, Bevacizumab, Oxaliplatin, Calcium folinate, 5-fluorouracil | Fujian Cancer Hospital | Rectal Cancer | 05/24 | 05/26 | | |
NCT06361979: SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases |
|
|
| Not yet recruiting | 2 | 30 | NA | SHR-A1811, Bevacizumab | Huihua Xiong | Breasr Cancer | 05/25 | 05/26 | | |
NCT06363552: A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 36 | RoW | SC0191, SC0191 + Bevacizumab, SC0191 + 5-FU/LV | Tianshu Liu | Metastatic Colorectal Cancer | 04/25 | 12/25 | | |
OBU-HCC-II-001, NCT06405061: A Prospective, Single-arm, Multicenter Phase II Clinical Study of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 40 | RoW | Adebrelimab, Bevacizumab, HAIC | Tianjin Medical University Cancer Institute and Hospital | Adebrelimab, Hepatocellular Carcinoma | 05/25 | 08/27 | | |
| Not yet recruiting | 2 | 94 | NA | Encorafenib, Cetuximab, Bevacizumab | Vall d'Hebron Institute of Oncology | Metastatic Colorectal Cancer | 05/27 | 05/29 | | |
NCT06397222: Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC |
|
|
| Recruiting | 2 | 23 | RoW | Sin-Bev-SIRT | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 04/27 | 04/27 | | |
NCT06408623: Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer |
|
|
| Not yet recruiting | 2 | 48 | NA | chidamide combined with Sintilimab and bevacizumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Liver Cancer | 05/25 | 05/26 | | |
IMMUNO-TH, NCT06254248: Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 50 | NA | Systemic therapy | Assistance Publique - Hôpitaux de Paris | Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment | 05/28 | 12/28 | | |
NCT06420973: RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression |
|
|
| Recruiting | 2 | 54 | RoW | RC48+carboplatin±bevacizumab | Peking University Cancer Hospital & Institute | Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | 05/27 | 09/27 | | |
| Active, not recruiting | 2 | 204 | Europe, Canada, Japan, US, RoW | NIS793, Bevacizumab, Modified FOLFOX6, 5FU+Leucovorin+Oxaliplatin, FOLFIRI, 5FU+Leucovorin+Irinotecan, Tislelizumab, VDT482 | Novartis Pharmaceuticals, Novartis Pharma AG | Metastatic Colorectal Cancer | 09/24 | 09/24 | | |
NCT02436993: Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab |
|
|
| Active, not recruiting | 2 | 120 | US | Carboplatin, Paraplatin, Paclitaxel, Taxol, Bevacizumab, Avastin, Trastuzumab, Herceptin, Pertuzumab, Perjeta | University of California, Irvine | Breast Carcinoma | 06/24 | 06/24 | | |
